Insider Trading Alert - HXL, NATI, COST, LGND And IDTI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 2, 2014, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $700.00 to $9,000,000.00.

Highlighted Stocks Traded by Insiders:

Hexcel Corporation (HXL) - FREE Research Report

Brubaker Lynn who is Director at Hexcel Corporation sold 2,790 shares at $44.37 on Jan. 2, 2014. Following this transaction, the Director owned 6,643 shares meaning that the stake was reduced by 29.58% with the 2,790-share transaction.

The shares most recently traded at $44.69, up $0.32, or 0.72% since the insider transaction. Historical insider transactions for Hexcel Corporation go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 15,000
  • 24-Week # shares sold: 15,000

The average volume for Hexcel Corporation has been 491,700 shares per day over the past 30 days. Hexcel Corporation has a market cap of $4.4 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are up 65.65% year-to-date as of the close of trading on Monday.

Hexcel Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of lightweight and high-performance structural materials for use in commercial aerospace, space and defense, and industrial applications. The company has a P/E ratio of 25.7. Currently there are 7 analysts that rate Hexcel Corporation a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HXL - FREE

TheStreet Quant Ratings rates Hexcel Corporation as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Hexcel Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

National Instruments Corporation (NATI) - FREE Research Report

Kodosky Jeffrey L who is Director at National Instruments Corporation sold 4,000 shares at $31.40 on Jan. 2, 2014. Following this transaction, the Director owned 975,180 shares meaning that the stake was reduced by 0.41% with the 4,000-share transaction.

The shares most recently traded at $32.02, up $0.62, or 1.92% since the insider transaction. Historical insider transactions for National Instruments Corporation go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 40,271
  • 24-Week # shares sold: 88,271

The average volume for National Instruments Corporation has been 386,600 shares per day over the past 30 days. National Instruments Corporation has a market cap of $3.9 billion and is part of the technology sector and computer software & services industry. Shares are up 21.35% year-to-date as of the close of trading on Monday.

National Instruments Corporation designs, manufactures, and sells tools to engineers and scientists worldwide. It offers LabVIEW, a system design software product for measurement and control; and LabVIEW Real-Time and LabVIEW FPGA that are strategic modular software add-ons. The stock currently has a dividend yield of 1.79%. The company has a P/E ratio of 57.0. Currently there is 1 analyst that rates National Instruments Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NATI - FREE

TheStreet Quant Ratings rates National Instruments Corporation as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full National Instruments Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Costco Wholesale Corporation (COST) - FREE Research Report

Lazarus Franz E who is Executive VP at Costco Wholesale Corporation sold 600 shares at $118.71 on Jan. 2, 2014. Following this transaction, the Executive VP owned 28,709 shares meaning that the stake was reduced by 2.05% with the 600-share transaction.

James Hamilton E who is Director at Costco Wholesale Corporation sold 11,900 shares at $118.84 on Jan. 2, 2014. Following this transaction, the Director owned 29,076 shares meaning that the stake was reduced by 29.04% with the 11,900-share transaction.

The shares most recently traded at $119.02, up $0.18, or 0.15% since the insider transaction. Historical insider transactions for Costco Wholesale Corporation go as follows:

  • 4-Week # shares sold: 8,000
  • 12-Week # shares sold: 114,802
  • 24-Week # shares sold: 130,802

The average volume for Costco Wholesale Corporation has been 1.9 million shares per day over the past 30 days. Costco Wholesale Corporation has a market cap of $52.1 billion and is part of the services sector and retail industry. Shares are up 20.3% year-to-date as of the close of trading on Monday.

Costco Wholesale Corporation, together with its subsidiaries, operates membership warehouses. The company offers branded and private-label products in a range of merchandise categories. The stock currently has a dividend yield of 1.05%. The company has a P/E ratio of 25.6. Currently there are 12 analysts that rate Costco Wholesale Corporation a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on COST - FREE

TheStreet Quant Ratings rates Costco Wholesale Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, growth in earnings per share, increase in net income and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Costco Wholesale Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Ligand Pharmaceuticals (LGND) - FREE Research Report

Foehr Matthew W who is EVP and COO at Ligand Pharmaceuticals bought 84 shares at $33.91 on Jan. 2, 2014. Following this transaction, the EVP and COO owned 45,013 shares meaning that the stake was reduced by 0.19% with the 84-share transaction.

Berkman Charles S who is VP, Gen. Counsel & Secretary at Ligand Pharmaceuticals bought 209 shares at $33.91 on Jan. 2, 2014. Following this transaction, the VP, Gen. Counsel & Secretary owned 27,145 shares meaning that the stake was reduced by 0.78% with the 209-share transaction.

The shares most recently traded at $52.60, up $18.69, or 35.52% since the insider transaction. Historical insider transactions for Ligand Pharmaceuticals go as follows:

  • 4-Week # shares sold: 6,000
  • 12-Week # shares sold: 6,499
  • 24-Week # shares bought: 2,043
  • 24-Week # shares sold: 9,943

The average volume for Ligand Pharmaceuticals has been 346,100 shares per day over the past 30 days. Ligand Pharmaceuticals has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are up 158.97% year-to-date as of the close of trading on Monday.

Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States. The company has a P/E ratio of 115.1. Currently there are 3 analysts that rate Ligand Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LGND - FREE

TheStreet Quant Ratings rates Ligand Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full Ligand Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Integrated Device Technology (IDTI) - FREE Research Report

Feld Peter A who is Director at Integrated Device Technology sold 426,780 shares at $10.15 on Jan. 2, 2014. Following this transaction, the Director owned 1.8 million shares meaning that the stake was reduced by 19.51% with the 426,780-share transaction.

The shares most recently traded at $10.18, up $0.03, or 0.25% since the insider transaction. Historical insider transactions for Integrated Device Technology go as follows:

  • 4-Week # shares sold: 1,891
  • 12-Week # shares bought: 20,000
  • 12-Week # shares sold: 1,891
  • 24-Week # shares bought: 60,000
  • 24-Week # shares sold: 291,804

The average volume for Integrated Device Technology has been 1.7 million shares per day over the past 30 days. Integrated Device Technology has a market cap of $1.5 billion and is part of the technology sector and electronics industry. Shares are up 38.77% year-to-date as of the close of trading on Monday.

Integrated Device Technology, Inc. designs, develops, manufactures, and markets a range of mixed signal semiconductor solutions for the communications, computing, and consumer industries worldwide. It operates in two segments, Communications, and Computing and Consumer. The company has a P/E ratio of 23.6. Currently there are 2 analysts that rate Integrated Device Technology a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IDTI - FREE

TheStreet Quant Ratings rates Integrated Device Technology as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Integrated Device Technology Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers